Device Trial Radar · NCT04101669
The RESET System Pivotal Clinical Trial (Protocol Revision K)
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
264
Planned (sponsor's estimate)
Start
Sep 9, 2019
Primary completion
Dec 30, 2027
Study completion Sep 30, 2029
Sponsor
- Lead sponsor
- Morphic Medical Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Biostatistical Consulting, Inc.
- First posted
- Sep 24, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study. A multi-center, double-blinded, randomized, sham-controlled trial to evaluate the safety and effectiveness of the RESET System plus moderate intensity lifestyle and dietary counseling compliant with 2024 ADA Standard of Care as compared to a sham control receiving moderate intensity lifestyle and dietary counseling. Both the treatment and sham group will practice medical management compliant with STEP-1 Study Guidelines. Patients will be randomized 3 (RESET):1 (Sham).
Conditions
- Diabetes type2
- Obesity
Interventions
RESET LinerDevice
The RESET System is provided as a single-use, sterile device and consists of an RESET Liner preloaded, packaged and sterilized within the RESET Delivery System. The RESET Delivery System is utilized to deliver the RESET Liner to the proximal small intestine. The RESET Liner is removed using the RESET Retrieval System. The RESET System incorporates no pharmacological, biological tissue or blood products.
ShamOther
Patient receives upper endoscopy but no treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1cTime frame: 9 Months
- SAE RateTime frame: 9 months
Locations
27 sites in 1 country. Site status is shown where the registry gives one.
Banner Health
Gilbert, Arizona · Recruiting
M3 Wake Research
Tucson, Arizona · Recruiting
MedStar Health Research Institute
Washington D.C., District of Columbia · Recruiting
24 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.